Loading clinical trials...
Loading clinical trials...
A Phase I, Non-randomized Open-label Study to Evaluate the Effect of BAY73-4506 (Regorafenib) on Probe Substrates of CYP 2C9 (Warfarin), 2C19 (Omeprazole) and 3A4 (Midazolam) in a Cocktail Approach (Group A) and on a Probe Substrate of CYP 2C8 (Rosiglitazone, Group B) in Patients With Advanced Solid Tumors
Conditions
Interventions
Regorafenib (Stivarga, BAY73-4506)
Warfarin
+3 more
Locations
4
Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
British Columbia Cancer Agency-Vancouver Centre
Vancouver, British Columbia, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Sir Mortimer B. Davis Jewish General Hospital
Montreal, Quebec, Canada
Start Date
August 2, 2011
Primary Completion Date
July 3, 2018
Completion Date
July 30, 2018
Last Updated
July 10, 2019
NCT07169851
NCT07213804
NCT00026884
NCT07159659
NCT06662786
NCT07191730
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions